Cordant, Inc. Crispr Therapeutics Ag Transaction History
Cordant, Inc.
- $192 Billion
- Q1 2025
A detailed history of Cordant, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cordant, Inc. holds 114 shares of CRSP stock, worth $4,408. This represents 0.0% of its overall portfolio holdings.
Number of Shares
114Holding current value
$4,408% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
484Shares Held
63.9MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$347 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$338 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$147 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$107 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$106 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.02B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....